p. 148−148
1735-367X
Vol.5/No.3
p. 148−155
1735-367X
Vol.5/No.3
p. 156−162
1735-367X
Vol.5/No.3
p. 163−170
1735-367X
Vol.5/No.3
p. 171−176
1735-367X
Vol.5/No.3
p. 177−180
1735-367X
Vol.5/No.3
0.1 IU/ml. IgG, IgA, and IgM levels were in the normal range for their age. Mean disease ac-tivity score was 4.9 (range: 0-16). There was no association between SLEDAI score and anti-tetanus antibody response. Conclusion: School age onset and immunosuppressive therapy does not seem to interfere with development of consistent immunity to tetanus vaccine in young SLE patients.]]>
p. 181−184
1735-367X
Vol.5/No.3
p. 185−188
1735-367X
Vol.5/No.3